ANI Pharmaceuticals (ANIP) vs. United Therapeutics Corporation (UTHR) Head-To-Head Comparison

ANI Pharmaceuticals (NASDAQ: ANIP) and United Therapeutics Corporation (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

56.0% of ANI Pharmaceuticals shares are owned by institutional investors. 31.8% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of United Therapeutics Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for ANI Pharmaceuticals and United Therapeutics Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
United Therapeutics Corporation 3 6 2 0 1.91

ANI Pharmaceuticals currently has a consensus price target of $67.33, suggesting a potential upside of 16.41%. United Therapeutics Corporation has a consensus price target of $135.50, suggesting a potential upside of 12.87%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than United Therapeutics Corporation.

Earnings and Valuation

This table compares ANI Pharmaceuticals and United Therapeutics Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $158.12 million 4.26 $59.01 million $0.46 125.74
United Therapeutics Corporation $1.63 billion 3.20 $1.01 billion $11.34 10.59

United Therapeutics Corporation has higher revenue and earnings than ANI Pharmaceuticals. United Therapeutics Corporation is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ANI Pharmaceuticals and United Therapeutics Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 3.35% 22.70% 11.48%
United Therapeutics Corporation 30.50% 26.24% 19.37%

Risk & Volatility

ANI Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, United Therapeutics Corporation has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats United Therapeutics Corporation on 7 of the 13 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply